HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Verge, following trial failure, rebrands its AI drug discovery ambitions

Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to patients who best benefit from them.

By BioPharma Dive · May 27, 2026 · via BioPharma Dive
Verge, following trial failure, rebrands its AI drug discovery ambitions

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
MannKind seeks long-awaited sales boost with inhaled insulin approval for kids
The WeekFiercePharma ↗
MannKind seeks long-awaited sales boost with inhaled insulin approval for kids
With a pediatric approval in hand for Afrezza, MannKind may finally have the boost it needs to make an impact …
May 30, 2026
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
The WeekFierceBiotech ↗
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T …
May 30, 2026
Leadership Change, Clinical Setbacks, and an ADC Milestone in a Busy FDA Week
The WeekBriefing
Leadership Change, Clinical Setbacks, and an ADC Milestone in a Busy FDA Week
Allogene’s founding CEO steps down, Agios halts development of tebapivat, AbbVie gains approval for Decnupaz, …
May 30, 2026